君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

休市中 09-25 16:08:14

18.310

+0.080

+0.44%

最高18.400	最低17.660	成交量36.66万
今开18.020	昨收18.230	日振幅4.06%
总市值188.04亿	流通市值47.61亿	总股本10.27亿
成交额661.58万	换手率0.14%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":18.31,"timestamp":1790323694004,"preClose":18.23,"halted":0,"volume":366600,"delay":0,"changeRate":0.004388370817333971,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"休市中","change":0.08,"latestTime":"09-25 16:08:14","open":18.02,"high":18.4,"low":17.66,"amount":6615768,"amplitude":0.040592,"askPrice":18.31,"askSize":22200,"bidPrice":18.16,"bidSize":6200,"shortable":3,"etf":0,"ttmEps":-0.451,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":18.23,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.09814792246813482,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":34.88,"timestamp":1790233200000,"preClose":35.78,"halted":0,"volume":14781800,"delay":0,"premium":"-54.99"}},"requestUrl":"/m/hq/s/01877/wiki","defaultTab":"wiki","newsList":[{"id":"2669646607","title":"君实生物（688180）披露2025年A股股票期权激励计划预留授予公告，9月24日股价下跌2.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669646607?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242580,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，君实生物报收于34.88元，较前一交易日下跌2.52%，最新总市值为358.11亿元。君实生物于近日披露《关于向2025年A股股票期权激励计划激励对象授予预留股票期权的公告》。公告显示，公司于2026年9月23日召开第四届董事会第二十三次会议，确定当日为2025年A股股票期权激励计划的预留授权日，向16名激励对象授予71.50万份股票期权，行权价格为46.67元/股。预留授予的等待期分别为12个月和24个月，行权比例分别为50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02846","BK1161","688180","BK1147","399300","02827","83130","82846","01877","159982","83188","BK1610","07233","BK0239","BK1515","BK1583","03130","03188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175879421","title":"君实生物2026年中期营收16.96亿元，经调整净利润1.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175879421","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175879421?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239239,"startTime":"0","endTime":"0","summary":"君实生物发布2026年中期财报，报告期内实现营收16.96亿元，同比增加45%。经调整净利润1.53亿元，较上年同期增加5.66亿元。同期毛利达12.79亿元，同比提升38%。研发投入6.44亿元，占营收约38%，同比下降14%。销售及分销费用5.07亿元，同比增加4%；管理费用2.79亿元，同比增加34%。期内经营活动净现金流出0.63亿元。核心产品特瑞普利单抗上半年国内销售收入达12.99亿元，同比增长36%，在推动营收增长中贡献突出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君实生物2026年中期营收16.96亿元，经调整净利润1.53亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0516423174.USD","LU1770034418.SGD","SG9999014674.SGD","LU2328871848.SGD","SG9999002463.SGD","LU0348825331.USD","LU1880383366.USD","688428","LU0456846285.SGD","LU0540923850.HKD","02162","01548","03347","BK1515","LU0348766576.USD","02269","LU1242518931.SGD","LU0348783233.USD","LU1303224171.USD","06990","BK1141","01877","BK1583","KURE","LU1242518857.USD","LU2399975544.HKD","LU2039709279.SGD","LU0828237510.HKD","09995","399441","BK4581","161726","LU0140636845.USD","06160","09926","SG9999002562.SGD","02696","XBI","09969","BK1576","LU0516422366.SGD","LU1961090484.USD","LU0561508036.HKD","HK0000306701.USD","LU0856984785.SGD","LU3063872942.SGD","02268","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LU0315179316.USD","LU0348766576.USD","LU0516423091.SGD","01093","LU2476274720.SGD","02616","LU1226287792.SGD","LU1251922891.USD","02142","06978","LU1770034418.SGD","LU0039217434.USD","BK1515","LU1719994722.HKD","09926","MEDX","LU0348784397.USD","LU0417516902.SGD","SG9999002562.SGD","06185","LU0314109678.HKD","159992","HK0000165453.HKD","KCE","LU1226288253.USD","LU2039709279.SGD","LU0320764599.SGD","02269","600109","LU0708995583.HKD","09688","LU0029874061.USD","01177","LU1993786604.SGD","LU0128526141.USD","06160","LU0828237510.HKD","01801","09995","LU0359202008.SGD","LU2097828805.USD","LU1152091754.HKD","LU3063872942.SGD","01877","IBBQ","LU0348735423.USD","IE00B5MMRT66.SGD","KURE","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669043862","title":"股市必读：君实生物新发布《君实生物第四届董事会第二十三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669043862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669043862?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:23","pubTimestamp":1790184190,"startTime":"0","endTime":"0","summary":"公司公告汇总：董事会审议通过2025年A股股票期权激励计划首次授予第一个行权期行权条件成就，同意205名激励对象行权共计1,146.75万份，同时注销174.00万份不符合条件的股票期权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1515","BK1161","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155909874","title":"君实生物预留授出71.5万份A股期权 首期行权条件达成并注销174万份期权","url":"https://stock-news.laohu8.com/highlight/detail?id=1155909874","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155909874?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:31","pubTimestamp":1790170290,"startTime":"0","endTime":"0","summary":"2026年9月23日，君实生物公告称，公司董事会审议通过多项与2025年A股股票期权激励计划相关的议案，核心内容如下：。本次向16名激励对象预留授出715,000份A股股票期权，对应715,000股A股，占公告日公司已发行股份总数的0.07%。授权日为2026年9月23日，行权价为每股人民币46.67元。因21名激励对象离职及2名激励对象绩效未达标，公司拟注销已授予但尚未行权的1,740,000份A股期权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147945578","title":"君实生物（01877）2025年A股期权激励首个行权期达标 可行权1146.75万份并同步授予71.50万份预留期权","url":"https://stock-news.laohu8.com/highlight/detail?id=1147945578","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147945578?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:06","pubTimestamp":1790168773,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司9月24日在港交所发布海外监管公告称，公司2025年A股股票期权激励计划首次授予部分的第一个行权期已满足行权条件，涉及可行权股票期权1146.75万份，占公司当前总股本的1.12%。与此同时，公司对因离职及绩效原因不得行权的174.00万份已授期权予以注销。\\n\\n公告同时披露，董事会确定2026年9月23日为预留授权日，向16名激励对象授予预留股票期权71.50万份，行权价格同为46.67元/股，约占公司当前总股本的0.07%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165877806","title":"君实生物（01877）董事会通过两项股权激励议案　逾1146.75万份期权进入首个行权期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165877806","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165877806?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:50","pubTimestamp":1790167839,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司9月24日公告称，公司第四届董事会第二十三次会议已于2026年9月23日召开并审议通过两项与2025年A股股票期权激励计划相关的议案。会议应出席董事14名，实到14名，符合《公司法》和公司章程的规定，所作决议合法有效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669547471","title":"9月21日君实生物现1笔大宗交易 机构净买入990.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669547471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669547471?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:48","pubTimestamp":1789984098,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日君实生物发生大宗交易，交易数据如下：大宗交易成交价格34.75元，相对当日收盘价折价0.63%，成交28.5万股，成交金额990.38万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。近三个月该股共发生19笔大宗交易，合计成交14.24万手，折价成交19笔。截至2026年9月21日收盘，君实生物报收于34.97元，上涨4.92%，换手率2.39%，成交量18.31万手，成交额6.34亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100023125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","BK1515","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156665","title":"智通AH统计|9月21日","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669156665?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:15","pubTimestamp":1789978506,"startTime":"0","endTime":"0","summary":"东北电气0.2392.251029.71%-19.83%浙江世宝3.90015.58378.46%-5.26%安德利果汁20.06077.99365.70%87.17%弘业期货2.2008.14343.18%22.10%晨鸣纸业0.6102.06304.92%28.60%中石化油服0.6702.25302.99%-0.92%南京熊猫电子股份3.1259.95281.44%20.56%钧达股份12.42038.77273.91%50.18%京城机电股份2.6108.12272.80%19.86%复旦张江2.6508.19270.19%-11.18%. 安德利果汁20.06077.99365.70%87.17%新华文轩8.06015.29127.17%59.28%钧达股份12.42038.77273.91%50.18%国民技术8.87522.51203.77%29.71%晨鸣纸业0.6102.06304.92%28.60%沃尔核材8.99517.19128.90%24.73%广合科技123.000185.9381.07%23.84%弘业期货2.2008.14343.18%22.10%美格智能19.88046.47179.98%21.66%南京熊猫电子股份3.1259.95281.44%20.56%. 备注：以上数据由智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；偏离值为当前溢价率与该股过去30天平均溢价率的差值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02701","01349","03678","00042","02338","03268","LU2097828631.EUR","00811","02827","02899","03328","06166","159982","83130","00991","01057","03986","01812","00553","83188","02846","03750","06745","03188","LU0607220059.USD","06127","01033","02768","LU0516422440.USD","02865","03308","06821","03143","09981","82846","01989","03200","00300","00187","EWH","399300","00317","02359","03130","01877","03968","07233","02475","02218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","01548","09969","02268","06990","02269","02162","02359","02696","09926","03347","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","06160","LU0326950275.SGD","LU0540923850.HKD","LU0561508036.HKD","LU1961090484.USD","LU0128522744.USD","LU0348767384.USD","HK0000165453.HKD","02269","02696","02359","LU0052750758.USD","01877","LU0456827905.SGD","02162","LU0348766576.USD","BK1610","KURE","399441","LU2488822045.USD","BK1515","LU1880383366.USD","06990","161726","LU2045819591.USD","LU2476274720.SGD","LU2242644610.SGD","LU0634319403.HKD","LU0516422952.EUR","09995","LU0244354667.USD","BK4588","LU0320764243.SGD","LU0327786744.USD","01548","LU1303224171.USD","LU0348784397.USD","09926","LU0463099449.HKD","LU0196878994.USD","LU0029874905.USD","LU0320764599.SGD","03347","XBI","BK1588","02268","LU1188198961.HKD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668813919","title":"生物医药概念走强 再鼎医药（09688）涨超4% 十部门出台医药工业十五五规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2668813919","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668813919?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:45","pubTimestamp":1789695942,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药概念走强，截至发稿，金斯瑞生物科技 涨4.78%，再鼎医药涨4.57%，君实生物涨3.32%，泰格医药涨1.93%，药明生物涨1.70%。消息面上，工业和信息化部、国家发展改革委等十部门联合发布《医药工业发展“十五五”规划》。《规划》提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991931","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","LU3063872942.SGD","LU0634319403.HKD","01548","LU0561508036.HKD","01877","LU1242518931.SGD","BK1610","BK1583","XBI","LU0140636845.USD","BK1161","BK4139","LU2488822045.USD","LU0572944931.SGD","LU0128526141.USD","SG9999002463.SGD","LU0979878070.USD","LU0516423091.SGD","LU0348735423.USD","LU0516423174.USD","LU0348827113.USD","LU0320764599.SGD","BK4531","LU0856984785.SGD","HK0000320264.USD","LU0043850808.USD","BK1141","399441","LU0128522744.USD","LU0181495838.USD","LU0417516902.SGD","KURE","LU0320764243.SGD","ZLAB","LU0029874061.USD","LU0417516738.SGD","BK1521","09688","LU0516422366.SGD","02269","LU0348825331.USD","BK4588","LU1688375341.USD","HK0000306685.HKD","LU0326950275.SGD","LU0456846285.SGD","LU0588546209.SGD","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658586","title":"港股异动 | 君实生物(01877)涨超3% 两款双特异性抗体新药均计划在年内启动关键III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658586","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667658586?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:15","pubTimestamp":1789366522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报17.11港元，成交额1995.51万港元。消息面上，9月14日，君实生物在2026年半年度业绩说明会上披露核心创新药管线的最新研发进展。公司明确表示，两款备受关注的双特异性抗体新药均计划在2026年内启动关键的III期临床研究。其中，靶向CD20/CD3的双抗药物JS203将正式进入III期临床阶段；而另一款靶向PD-1/VEGF的双抗药物JS207目前正处于II期临床研究阶段，正在多个瘤种中积极开展与化疗、单抗及ADC等不同治疗手段的联合用药探索，并同样预计于2026年内启动III期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","BK4588","KCAI","01877","BK1583","VXUS","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU1064130708.USD","LU0572944931.SGD","KURE","LU2039709279.SGD","BK0028","IE0008369823.USD","LU1655091616.SGD","02142","06030","LU1720050803.USD","06160","LU0405327494.USD","LU0561508036.HKD","LU0979878070.USD","LU0181495838.USD","06185","LU1997245177.USD","LU1580142542.USD","LU1794554557.SGD","LU1961090484.USD","SG9999004220.SGD","LU2148510915.USD","LU0348825331.USD","IE00B543WZ88.USD","LU2580892862.HKD","LU1226287792.SGD","LU1880383366.USD","LU0463099449.HKD","KCE","BK1161","09995","LU0417516738.SGD","01177","LU0348783233.USD","LU1226287875.USD","LU1820825898.SGD","LU1255011170.USD","01093","09926","LU0516422952.EUR","LU1813983027.USD","LU1969619763.USD","02269","02616","BK1141","01877","600030","LU0819121731.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665188703","title":"破发股君实生物跌2.15% 2020年上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665188703","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665188703?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:33","pubTimestamp":1788769993,"startTime":"0","endTime":"0","summary":"中国经济网北京9月7日讯 君实生物 今日收报32.77元，跌幅2.15%。该股目前处于破发状态。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。　　经计算，君实生物两次募集资金合计86.12亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260907/32362114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK1583","BK1161","01877","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665362741","title":"股市必读：君实生物新发布《君实生物H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665362741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665362741?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:17","pubTimestamp":1788715027,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，君实生物报收于33.49元，下跌0.77%，换手率1.13%，成交量8.63万手，成交额2.91亿元。当日关注点交易信息汇总：9月4日主力资金净流出301.79万元，占总成交额1.04%。公司公告汇总：截至2026年8月31日，君实生物H股与A股股本、已发行股份及库存股份数目均无变动，公众持股量符合上市规则要求。H股及A股股票期权激励计划分别存续13,210,000份和24,700,000份，本月无新增行权或股份变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","BK1515","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665636570","title":"每周股票复盘：君实生物（688180）股东拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665636570","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665636570?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:49","pubTimestamp":1788634151,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，君实生物报收于33.49元，较上周的33.56元下跌0.21%。本周关注点公司公告汇总：上海檀英计划减持不超20,533,796股，减持比例不超过公司总股本的2%。H股公告：截至2026年8月31日，公司H股与A股股本及已发行股份数目均无变动。公司公告汇总君实生物关于股东减持股份计划的公告：截至公告披露日，上海檀英持有公司38,925,626股，占总股本的3.7914%，股份来源于IPO前取得。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1583","BK1161","688180","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153539419","title":"君实生物(01877)拟于9月14日召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1153539419","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153539419?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:55","pubTimestamp":1788526540,"startTime":"0","endTime":"0","summary":"本次说明会将围绕公司2026年半年度经营成果及财务指标进行交流。投资者可于2026年9月7日至9月11日16:00前，通过上证路演中心“提问预征集”栏目或发送邮件至公司邮箱info@junshipharma.com提交问题，届时公司将在说明会现场集中解答投资者普遍关注的事项。公司已于2026年8月27日在上海证券交易所网站披露2026年半年度报告。说明会结束后，投资者可通过上证路演中心查看会议回放及主要内容。如有疑问，可联系公司证券部，电话021-61058800-1153，或邮件至info@junshipharma.com。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733252","title":"君实生物：公司将于9月14日召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733252","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664733252?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:32","pubTimestamp":1788525120,"startTime":"0","endTime":"0","summary":"证券日报网讯9月4日，君实生物发布公告称，公司计划于2026年9月14日10：00-11：00举行2026年半年度业绩说明会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.0578},{"period":"1month","weight":-0.0383},{"period":"3month","weight":0.1913},{"period":"6month","weight":-0.1877},{"period":"1year","weight":-0.4078},{"period":"ytd","weight":-0.142}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":-0.000677},{"month":8,"riseRate":0.125,"avgChangeRate":-0.039004},{"month":9,"riseRate":0.25,"avgChangeRate":-0.018947},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}